Lurbinectedin in small cell lung cancer: real‐world experience of a multicentre national early access programme
Internal Medicine Journal · 2024
DOI: 10.1111/imj.16348 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Internal Medicine Journal, 2024. Verfasst von Marliese Alexander und 11 weiteren Autor:innen. Beteiligte Einrichtung: Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia. Hauptthemen laut MEDLINE: Small Cell Lung Carcinoma, Lung Neoplasms, Carbolines, Heterocyclic Compounds, 4 or More Rings. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Specialised Therapeutics.
Abstract (Originalsprache)
Background and Aims Lurbinectedin is a novel oncogenic transcription inhibitor active in several cancers, including small cell lung cancer (SCLC). We aimed to describe the first Australian experience of the clinical efficacy and tolerability of lurbinectedin for the treatment of SCLC after progression on platinum‐containing therapy.
Methods
Multicentre real‐world study of individuals with SCLC initiating lurbinectedin monotherapy (3.2 mg/m 2 three‐weekly) on an early access programme between May 2020 and December 2021. Key outcomes were clinical utilisation, efficacy and tolerability. Progression‐free survival (PFS) and overall survival (OS) were calculated using the Kaplan–Meier method. Outcome data were collected within the AUstralian Registry and biObank of thoRacic cAncers (AURORA).
Results
Data were analysed for 46 individuals across seven sites. Lurbinectedin was given as second‐ (83%, 38/46) or subsequent‐ (17%, 8/46) line therapy, mostly with prior chemoimmunotherapy (87%, 40/46). We report dose modifications (17%, 8/46), interruptions/delays (24%, 11/46), high‐grade toxicities (28%, 13/46) and hospitalisations (54%, 25/46) during active treatment. The overall response rate was 33% and the disease control rate was 50%. Six‐month OS was 44% (95% confidence interval (CI): 29.0–57.1). Twelve‐month OS was 15% (95% CI: 6.5–26.8). From lurbinectedin first dose, the median PFS was 2.5 months (95% CI: 1.8–2.9) and OS was 4.5 months (95% CI: 3.5–7.2). From SCLC diagnosis, the median OS was 12.9 months (95% CI: 11.0–17.2). Individuals with a longer chemotherapy‐free interval prior to lurbinectedin had longer PFS and OS.
Conclusion
This real‐world national experience of lurbinectedin post‐platinum chemotherapy and immunotherapy for individuals with SCLC was similar to that reported in clinical trials.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
- Sir Peter MacCallum Department of Oncology, The University of Melbourne, Melbourne, Victoria, Australia.
- Austin Hospital, Olivia Newton-John Cancer Research Institute, Melbourne, Victoria, Australia.
- School of Cancer Medicine, La Trobe University, Melbourne, Victoria, Australia.
- Division of Medicine, Dentistry and Health Sciences, The University of Melbourne, Melbourne, Victoria, Australia.
- Saint John of God Subiaco Hospital, Perth, Western Australia, Australia.
ORCID-Profile: Marliese Alexander
Förderung
- Specialised Therapeutics
Zitieren
APA
Alexander, M., Rogers, J., Parakh, S., Mitchell, P., Clay, T. D., Kao, S., Hughes, B. G. M., Itchins, M., Kong, B. Y., Pavlakis, N., Solomon, B. J., & John, T. (2024). Lurbinectedin in small cell lung cancer: real‐world experience of a multicentre national early access programme. Internal Medicine Journal. https://doi.org/10.1111/imj.16348
Vancouver
Alexander M, Rogers J, Parakh S, Mitchell P, Clay TD, Kao S, et al. Lurbinectedin in small cell lung cancer: real‐world experience of a multicentre national early access programme. Internal Medicine Journal. 2024. doi:10.1111/imj.16348
BibTeX
@article{Alexander2024,
author = {Alexander, Marliese and Rogers, Jennifer and Parakh, Sagun and Mitchell, Paul and Clay, Timothy D and Kao, Steven and Hughes, Brett G M and Itchins, Malinda and Kong, Benjamin Y and Pavlakis, Nick and Solomon, Benjamin J and John, Thomas},
title = {Lurbinectedin in small cell lung cancer: real‐world experience of a multicentre national early access programme},
journal = {Internal Medicine Journal},
year = {2024},
doi = {10.1111/imj.16348}
}
EUVIMED